froidir 25 mg tabletti
orion corporation - clozapinum - tabletti - 25 mg - klotsapiini
froidir 100 mg tabletti
orion corporation - clozapinum - tabletti - 100 mg - klotsapiini
diviseq tabletti
orion oyj - estradioli valeras,medroxyprogesteroni acetas - tabletti - medroksiprogesteroni ja estrogeeni
paracetamol-ratiopharm 500 mg tabletti
ratiopharm gmbh - paracetamol - tabletti - 500 mg - parasetamoli
fludent anis 0.25 mg f imeskelytabletti
actavis group ehf. - natrii fluoridum - imeskelytabletti - 0.25 mg f - natriumfluoridi
fludent hallon 0.25 mg f imeskelytabletti
actavis group ehf. - natrii fluoridum - imeskelytabletti - 0.25 mg f - natriumfluoridi
tizanidin orion 2 mg tabletti
orion corporation - tizanidine - tabletti - 2 mg - titsanidiini
tizanidin orion 4 mg tabletti
orion corporation - tizanidine - tabletti - 4 mg - titsanidiini
cisatracurium fresenius kabi 2 mg/ml injektio-/infuusioneste, liuos
fresenius kabi ab - cisatracurium besilate - injektio-/infuusioneste, liuos - 2 mg/ml - sisatrakuuri
zejula
glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastiset aineet - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.